{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T05:01:24Z","timestamp":1751086884534},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T00:00:00Z","timestamp":1427932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,4,2]],"date-time":"2015-04-02T00:00:00Z","timestamp":1427932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s12185-015-1791-3","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T05:00:31Z","timestamp":1428037231000},"page":"53-58","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine"],"prefix":"10.1007","volume":"102","author":[{"given":"Momoko","family":"Nishikori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Hishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norimitsu","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Haga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,2]]},"reference":[{"key":"1791_CR1","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"1791_CR2","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine\u2013rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944\u201352.","journal-title":"Blood"},{"key":"1791_CR3","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31:2103\u20139.","journal-title":"J Clin Oncol"},{"key":"1791_CR4","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1200\/JCO.2010.33.8061","volume":"29","author":"K Fischer","year":"2011","unstructured":"Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and\/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559\u201366.","journal-title":"J Clin Oncol"},{"key":"1791_CR5","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","volume":"30","author":"K Fischer","year":"2012","unstructured":"Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209\u201316.","journal-title":"J Clin Oncol"},{"key":"1791_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","volume":"31","author":"G Damaj","year":"2013","unstructured":"Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31:104\u201310.","journal-title":"J Clin Oncol"},{"key":"1791_CR7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","volume":"31","author":"AJ Moskowitz","year":"2013","unstructured":"Moskowitz AJ, Hamlin PA Jr, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31:456\u201360.","journal-title":"J Clin Oncol"},{"key":"1791_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12185-014-1521-2","volume":"99","author":"AM Intlekofer","year":"2014","unstructured":"Intlekofer AM, Younes A. From empiric to mechanism-based therapy for peripheral T cell lymphoma. Int J Hematol. 2014;99:249\u201362.","journal-title":"Int J Hematol"},{"key":"1791_CR9","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/j.1349-7006.2010.01635.x","volume":"101","author":"K Ohmachi","year":"2010","unstructured":"Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101:2059\u201364.","journal-title":"Cancer Sci"},{"key":"1791_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.5144\/1658-3876.2011.157","volume":"4","author":"B Malipatil","year":"2011","unstructured":"Malipatil B, Ganesan P, Sundersingh S, Sagar TG. Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. Hematol Oncol Stem Cell Ther. 2011;4:157\u201360.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"1791_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D385N6C9JF","volume":"16","author":"HS Alamdari","year":"2010","unstructured":"Alamdari HS, Pinter-Brown L, Cassarino DS, Chiu MW. Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J. 2010;16:1.","journal-title":"Dermatol Online J"},{"key":"1791_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12185-012-1012-2","volume":"95","author":"A Gavini","year":"2012","unstructured":"Gavini A, Telang GH, Olszewski AJ. Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. Int J Hematol. 2012;95:311\u20134.","journal-title":"Int J Hematol"},{"key":"1791_CR13","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1016\/j.leukres.2012.03.006","volume":"36","author":"M Lambertini","year":"2012","unstructured":"Lambertini M, Del Mastro L, Gardin G, et al. Stevens-Johnson syndrome after treatment with bendamustine. Leuk Res. 2012;36:e153\u20134.","journal-title":"Leuk Res"},{"key":"1791_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2169\/internalmedicine.52.8206","volume":"52","author":"K Ito","year":"2013","unstructured":"Ito K, Shimizu N, Watanabe K, et al. Analysis of viral infection by multiplex polymerase chain reaction assays in patients with liver dysfunction. Intern Med. 2013;52:201\u201311.","journal-title":"Intern Med"},{"key":"1791_CR15","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","volume":"22","author":"AM Evens","year":"2011","unstructured":"Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011;22:1170\u201380.","journal-title":"Ann Oncol"},{"key":"1791_CR16","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1136\/ard.2010.148783","volume":"70","author":"JL Lan","year":"2011","unstructured":"Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70:1719\u201325.","journal-title":"Ann Rheum Dis"},{"key":"1791_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3816\/CLML.2010.n.002","volume":"10","author":"BD Cheson","year":"2010","unstructured":"Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. 2010;10:21\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1791_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1046\/j.1365-4362.1998.00507.x","volume":"37","author":"SN Matthews","year":"1998","unstructured":"Matthews SN, Cockerell CJ. Prurigo nodularis in HIV-infected individuals. Int J Dermatol. 1998;37:401\u20139.","journal-title":"Int J Dermatol"},{"key":"1791_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/archderm.1989.01670170043005","volume":"125","author":"B Liautaud","year":"1989","unstructured":"Liautaud B, Pape JW, DeHovitz JA, et al. Pruritic skin lesions. A common initial presentation of acquired immunodeficiency syndrome. Arch Dermatol. 1989;125:629\u201332.","journal-title":"Arch Dermatol"},{"key":"1791_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jaad.2011.11.923","volume":"67","author":"JP Afonso","year":"2012","unstructured":"Afonso JP, Tomimori J, Michalany NS, et al. Pruritic papular eruption and eosinophilic folliculitis associated with human immunodeficiency virus (HIV) infection: a histopathological and immunohistochemical comparative study. J Am Acad Dermatol. 2012;67:269\u201375.","journal-title":"J Am Acad Dermatol"},{"key":"1791_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2133.1994.tb08527.x","volume":"131","author":"RA Wakeel","year":"1994","unstructured":"Wakeel RA, Urbaniak SJ, Armstrong SS, et al. Idiopathic CD4\u00a0+\u00a0lymphocytopenia associated with chronic pruritic papules. Br J Dermatol. 1994;131:371\u20135.","journal-title":"Br J Dermatol"},{"key":"1791_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2332\/allergolint.10-RAI-0260","volume":"59","author":"T Shiohara","year":"2010","unstructured":"Shiohara T, Kurata M, Mizukawa Y, Kano Y. Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruptions and those under immunosuppressive therapy. Allergol Int. 2010;59:333\u201343.","journal-title":"Allergol Int"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1791-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-015-1791-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1791-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1791-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T04:52:41Z","timestamp":1691556761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-015-1791-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["1791"],"URL":"https:\/\/doi.org\/10.1007\/s12185-015-1791-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,2]]},"assertion":[{"value":"14 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}